ϩ channels in a variety of tissues, leading to potentially serious side effects when used clinically. We have created a series of novel local anesthetics by connecting benzocaine (BZ) to the sulfhydryl-reactive group methanethiosulfonate (MTS) via variable-length polyethylether linkers (L) (MTS-LX-BZ [X represents 0, 3, 6, or 9]). The application of MTS-LX-BZ agents modified native rat cardiac as well as heterologously expressed human heart (hH1) and rat skeletal muscle (rSkM1) Na ϩ channels in a manner resembling that of free BZ. Like BZ, the effects of MTS-LX-BZ on rSkM1 channels were completely reversible. In contrast, MTS-LX-BZ modification of heart and mutant rSkM1 channels, containing a pore cysteine at the equivalent location as cardiac Na ϩ channels (ie, Y401C), persisted after drug washout unless treated with DTT, which suggests anchoring to the pore via a disulfide bond. Anchored MTS-LX-BZ competitively reduced the affinity of cardiac Na ϩ channels for lidocaine but had minimal effects on mutant channels with disrupted local anesthetic modification properties. These results establish that anchored MTS-LX-BZ compounds interact with the local anesthetic binding site (LABS). Variation in the linker length altered the potency of channel modification by the anchored drugs, thus providing information on the spatial relationship between the anchoring site and the LABS. Our observations demonstrate that local anesthetics can be anchored to the extracellular pore cysteine in cardiac Na ϩ channels and dynamically interact with the intracellular LABS. These results suggest that nonselective agents, such as local anesthetics, might be made more selective by linking these agents to target-specific anchors. (Circ Res. 1999;85:88-98.)
L ocal anesthetics and related Na ϩ channel modifiers preferentially bind to the open or inactivated conformations of Na ϩ channels, 1,2 thus blocking Na ϩ current and reducing cellular excitability. As a result, these agents are used clinically to treat a variety of conditions. For example, the elimination of pain and the management of seizures are achieved by blocking nerve Na ϩ channels with local anesthetics. 2 On the other hand, these agents are used in controlling the symptoms associated with skeletal muscle diseases, such as hyperkalemic periodic paralysis and other related muscle myotonias. 3 In heart, Na ϩ channel blockers are used to treat patients with ischemia-related arrhythmias 4 and the congenital long-QT syndrome, LQT3. 5 There is also a recent report suggesting that local anesthetic might be useful in the treatment of torsade de pointes and related arrhythmias. 6 The ability of local anesthetics to target different tissue-specific Na ϩ channel homologues in various clinical applications highlights the nonselective nature of these agents. Indeed, indiscriminate blockade of Na ϩ channels regardless of tissue location is responsible for many of the side effects associated with their use. Despite these observations, local anesthetics do block Na ϩ channels with slightly higher potency in heart compared with nerve or skeletal muscle channels possibly because of longer cardiac action potentials, which promotes high-affinity binding to inactivated channels. 1, 7, 8 Alternatively, this modest preferential block of cardiac Na ϩ channels might result from an intrinsically greater affinity of drug binding 9, 10 and/or differences in steady-state inactivation gating. 11 Despite these modest differences in drug binding between tissue-specific Na ϩ channel homologues, local anesthetics bind to all voltage-gated Na ϩ channel pores and inhibit ionic current by either directly occluding ion flow through open channels or by promoting channel inactivation. 1, 2 Moreover, the site for local anesthetic binding has been localized to a pair of aromatic residues within the sixth transmembrane segment of domain IV, 12 which are conserved between various tissue-specific Na ϩ channel homologues [13] [14] [15] [16] and therefore cannot be responsible for the observed differences in binding. Molecular models of Na ϩ channels place these aromatic residues deep within the channel pore on its intracellular face. 17 This location is supported by biophysical studies establishing that internally perfused, permanently charged local anesthetics traverse Ϸ70% of the transmembrane electric field to reach its binding site. 18 On the other hand, externally applied Cd 2ϩ senses Ϸ21% of the transmembrane electric field when binding to a pore-lining cysteine residue located in the ascending limb of the P (pore) loop in domain I of cardiac Na ϩ channels ( Figure 1A ). 19, 20 These observations suggest that the external Cd 2ϩ binding site in domain I is located in close proximity to the local anesthetic binding site (LABS) in domain IV.
The relationship of these 2 pore regions was assessed in this study by linking the hydrophobic local anesthetic benzocaine (BZ) to the sulfhydryl reactive methanethiosulfonate (MTS) group via a variable length linker (L) ( Figure 1B ). We took advantage of previous studies establishing that the unique cysteine residue in the external pore of cardiac Na ϩ channels 19 -21 ( Figure 1A ) reacts readily with externally applied sulfhydryl-modifying agents. We hypothesized that these drugs would anchor to the extracellular pore cysteine and interact with the intracellular LABS provided the linker was sufficiently long ( Figure 1C ). The hydrophobic local anesthetic benzocaine was chosen for these studies, because this agent does not rely on hydrophilic pathways when binding to the LABS, 7 which might otherwise hamper drug access. Our experiments demonstrate a very close physical relationship between the unique cysteine in the external pore of the cardiac Na ϩ channel and the LABS. Our results suggest a novel paradigm for creating target-specific drugs wherein a nonselective drug, such as a local anesthetic or Ca 2ϩ channel blocker, is linked to an anchor that is designed to interact with a chosen, distinct molecular site on the desired channel protein.
Materials and Methods

Site-Directed Mutagenesis
Site-directed mutagenesis was performed using uracil-enriched single-stranded DNA according to the methods of Kunkel 22 and confirmed by dideoxy nucleotide sequencing. 23 A 1.9-kb BamHISphI or a 2.5-kb SphI-KpnI fragment of the rSkM1 15 Na ϩ channel pore mutant was subcloned into pGEM-11f ϩ or pGEM-7f ϩ (Promega), respectively. The mutant cassette was subcloned into the full-length rSkM1 Na ϩ channel construct in pGW1-CMV (British Biotechnology).
Heterologous Channel Expression and Recording
Oocytes were removed from female Xenopus laevis frogs anesthetized by immersion in a solution containing 0.2% 3-aminobenzoic acid ethyl ester (tricaine; Sigma). Oocytes were digested for 60 to 90 minutes with 1.5 mg/mL collagenase (Type 1A, Sigma) dissolved in a solution containing (in mmol/L) NaCl 82.5, KCl 2, MgCl 2 1, and HEPES 5 (pH 7.6 with NaOH). Nuclear injections were performed on healthy stage IV through VI oocytes with either the hH1 24 or rSkM1 ␣-subunit cDNA (5 ng per 50 nL) subcloned into pcDNA3 (Invitrogen) or pGW1H (British Biotechnology), respectively. The rSkM1 was coexpressed with the rat brain ␤ 1 subunit 25 (1:5 wt/wt ratio) to reconstitute native channel behavior. 26 Oocytes were incubated in a solution (ND96) containing (in mmol/L) NaCl 96, KCl 2, BaCl 2 1, MgCl 2 1, and HEPES 5 (pH 7.6) and supplemented with 5 pyruvate, 0.5 theophylline, and 50 g/mL gentamicin. Two-electrode voltage-clamp recordings were performed at room temperature using a Warner OC-725C amplifier on oocytes 1 to 5 days after injection. Only oocytes with peak Na ϩ currents Ͻ6 A were used in our studies to minimize voltage-clamping errors. Agarose-plugged electrodes (TW120F-6; World Precision Instruments) were pulled using a Sutter P-87 horizontal puller and were filled with 3 mol/L KCl, having a final resistance of 1 to 3 M⍀. Recording solution was ND96.
Rat Ventricular Myocyte Isolation and Patch-Clamp Recording
Rat ventricular cardiac myocytes were isolated as described previously. 27 Briefly, male Sprague-Dawley rats (250 to 300 g) were heparinized (3000 U/kg) and anesthetized with 150 mg/kg pentobarbital. Hearts were excised and retrogradely perfused for 5 minutes with a Krebs-Hensleit buffer consisting of (in mmol/L) NaCl 123, KCl 5.4, CaCl 2 1, MgSO 4 1.2, NaH 2 PO 4 1.2, NaHCO 3 20, and glucose 5.6 and equilibrated with a 95% O 2 -5% CO 2 mixture (pH 7.4). Next, the hearts were perfused for 5 minutes with a calciumfree Krebs-Hensleit solution followed by perfusion for 8 minutes with the same solution containing collagenase (type II, 0.6 mg/mL, Boehringer Mannheim) and protease (type XIV, 0.05 mg/mL, Sigma). At the end of the digestion period, hearts were perfused for 5 minutes with an enzyme-free high-K ϩ solution (KB) consisting of (in mmol/L) KCl 120, MgCl 2 1, K 2 -EGTA 0.5, glucose 10, and HEPES 20 (pH to 7.4 with KOH). The hearts were dismounted, and the atria and aorta were removed. Ventricular tissue was cut into small pieces, and cells were mechanically isolated by trituration with a Pasteur pipette and filtering through nylon mesh. Cells were stored Figure 1 . A, Sequence alignment of a pore forming region of domain I of different rat Na ϩ channel isoforms. Numbers denote amino acid position within the primary sequence. The unique cysteine residue in the heart isoform is shown within the box. B, Structure of benzocaine, MTS-L0-BZ, and the extended linker MTS-LX-BZ derivatives. Linker lengths were extended with polyethylether units, where n is 1, 2, or 3. C, Schematic diagram of local anesthetic drug anchoring to cardiac Na ϩ channels. The local anesthetic moiety interacts with the LABS on the channel protein in a dynamic manner.
in KB solution until required. Only calcium-tolerant, rod-shaped, quiescent myocytes with clear cross-striations were used for electrophysiological recordings. Na ϩ currents were recorded using the whole-cell patch-clamp configuration 28 with an Axopatch 200-A amplifier (Axon Instruments). Rat cardiac ventricular myocytes were placed in a 1-mL bath and perfused with extracellular solution with the following composition (in mmol/L): tetramethylammonium chloride 135, NaCl 5, CaCl 2 1, MgCl 2 1, glucose 10, and HEPES 10 (pH to 7.4 with tetramethylammonium hydroxide). Recording electrodes were fabricated from borosilicate glass (TW150F-4, World Precision Instruments), pulled on a Sutter puller, and heat polished to a final resistance of Ͻ1 M⍀ when filled with intracellular solution. The intracellular solution consisted of (in mmol/L) CsF 150, EGTA 10, and HEPES 10 (pH to 7.2 with CsOH). Series resistance compensation was 60% to 80%.
Experimental Protocols and Data Analysis
Whole-cell Na ϩ current-voltage relationships, steady-state inactivation, and recovery from inactivation were recorded from oocytes or rat ventricular myocytes. Cells were then exposed to the methanethiosulfonate benzocaine (MTS-LX-BZ [X represents 0, 3, 6, or 9]) compounds or benzocaine (500 mol/L) for at least 10 minutes to allow for complete channel modification. Washout of the drugs was performed for 5 to 10 minutes with recording solution. MTS-LX-BZ, benzocaine, and benzyl methanethiosulfonate (MTSBN) were dissolved in DMSO and diluted to the desired concentration. Lidocaine and 2-hydroxyethyl methanethiosulfonate (MTSHE) were dissolved in ND96. The final concentration of DMSO (0.01%) had no significant effect on any parameters measured. MTS-LX-BZ compounds were synthesized at Toronto Research Chemicals, Inc. MTSBN and MTSHE were purchased from Toronto Research Chemicals, Inc. Benzocaine and lidocaine were purchased from Sigma.
Whole-cell currents were elicited by 50-ms step depolarizations from -80 to ϩ60 mV from a holding potential of -100 mV (oocytes) or -120 mV (cardiac myocytes). Leak and capacitance subtraction were performed as described previously. 31 Steady-state inactivation was determined using a standard 2-pulse protocol. Data were normalized to the current amplitude recorded at -140 mV. Normalized steady-state inactivation relationships were fit with a single Boltzmann distribution, A 1 /(1ϩexp[(V-V 1 ⁄2)/k])ϩA 2 , where V 1/2 is the voltage of half inactivation, k is the slope factor, A 1 is the amplitude of the relationship, and A 2 is the amplitude of the noninactivating component. Recovery from inactivation was assessed with a 2-pulse protocol with identical 50-ms step depolarizations to -10 mV from a holding potential of -100 mV separated by a variable recovery period. The data for the recovery from inactivation were fit with the biexponential function, 1-{A fast /[1ϩexp(-x/ fast )]ϩA slow /[1ϩexp(-x/ slow )]}, where A fast and A slow are the amplitudes and fast and slow are the time constants of the fast and slow components, respectively. Data acquisition and analysis were performed using custom-written software.
Curve fitting was performed using a nonlinear least-squares iterative method that uses Marquardt-Levenberg algorithms. Statistical analysis was performed using a 1-way ANOVA followed by a Student-Newman-Keuls test. 29 A P value Ͻ0.05 was used to denote statistical difference between groups. Data are expressed as meanϮSEM. Figure 2A shows that exposure of human heart (hH1) Na ϩ channels expressed in Xenopus oocytes to 500 mol/L benzocaine resulted in a 43Ϯ3% reduction in peak current measured at -10 mV (nϭ5). The effects of benzocaine on peak currents were completely reversed after 10 minutes of drug washout. The application of MTS-L0-BZ at a concentration of 500 mol/L reduced peak hH1 Na ϩ currents to 62Ϯ8% (nϭ7) of control ( Figure 2A ). This reduction was not reversed after drug washout (ie, reduced to 49Ϯ8% of control), which indicates that most channels were irreversibly modified by MTS-L0-BZ (also see below). In contrast, application of MTS-L0-BZ (500 mol/L) to rat skeletal muscle Na ϩ channels (rSkM1) lacking a pore cysteine resulted in a 35Ϯ5% (nϭ5) current reduction, which was completely reversed on drug washout (Figure 2A ).
Results
To establish whether MTS-L0-BZ interacted specifically with the cysteine pore residue in hH1 channels (Figure 1 ), an equivalent cysteine residue was introduced into the rSkM1 channel pore (Y401C). 19 Y401C channels resemble cardiac Na ϩ channels in relation to block by tetrodotoxin and Cd 2ϩ and to single-channel conductance 19 but are otherwise similar to wild-type rSkM1 channels. A 10-minute exposure of Y401C channels to 500 mol/L MTS-L0-BZ followed by a 5-minute washout resulted in an irreversible reduction in current amplitude (38Ϯ4%, nϭ5), as observed in hH1 channels ( Figure 2A ). Longer washout periods did not restore peak current amplitude to predrug values. These data are consistent with a specific interaction of MTS-L0-BZ with a cysteine residue in the extracellular face of the pore.
To further verify that MTS-L0-BZ reacted specifically with the cysteine pore residue in both hH1 and Y401C, the effects of this drug on the Cd 2ϩ sensitivity of the channels were examined. Modification of hH1 and Y401C channels with external application of methanethiosulfonate compounds is known to reduce sensitivity to block by Cd 2ϩ and Zn 2ϩ by cross-linking with extracellular reduced free sulfhydryl groups. 20, 21, 30 Accordingly, application of reducing agents such as DTT is expected to reverse the effects of methanethiosulfonate modification on Na ϩ channels after drug washout. Modification with MTS-L0-BZ (500 mol/L) reduced the sensitivity of hH1 channels to Cd 2ϩ block (IC 50 ) from 50Ϯ8 to 1552Ϯ245 mol/L (nϭ3; PϽ0.05) and for Y401C channels from 16Ϯ3 to 1081Ϯ322 mol/L (nϭ3; PϽ0.01) ( Figure 3C ). The Cd 2ϩ sensitivity of the MTS-L0-BZ-modified Y401C channels is similar to that observed for the wild-type rSkM1 channel. 30 Figures 3A and 3B show that the application of MTS-L0-BZ reduced peak Y401C Na ϩ currents and the rate of recovery from inactivation after washout. Subsequent application of the sulfhydryl-reducing agent DTT (10 mmol/L) completely restored peak current amplitude ( Figure 3A ), the rate of recovery from inactivation ( Figure  3B ), and Cd 2ϩ sensitivity of Y401C channels previously modified with MTS-L0-BZ ( Figure 3C ). These data suggest that MTS-L0-BZ reacts with the pore cysteine residue and that the effects are not the result of nonspecific modification of the channel protein.
Effects of Methanethiosulfonate-Benzocaine (MTS-L0-BZ) on Na ؉ Channel Inactivation
Local anesthetic agents alter the inactivation properties of Na ϩ channels, leading to leftward shifts in the voltage dependence of steady-state inactivation and a slowing in the rate of recovery from inactivation. [7] [8] [9] [10] [11] These effects stem from high-affinity binding of these compounds to the inactivated state of Na ϩ channels, which results in a stabilization of the inactivated state. 7, 8 Therefore, we investigated whether anchoring benzocaine to an external pore residue on Na ϩ 90 Circulation Research July 9, 1999 channel truly allows access to the LABS, thus leading to the changes in Na ϩ channel inactivation as observed with other local anesthetics. The effects of MTS-L0-BZ (500 mol/L) on steady-state inactivation of hH1 channels were studied using a standard 2-pulse protocol; channels were depolarized to various conditioning potentials for 50 ms from -140 to -20 mV from a holding potential of -100 mV followed by a 50-ms test pulse to -10 mV. Only data from -120 to -20 mV are shown in Figure 2 . The 50-ms conditioning pulse was sufficient to allow for equilibrium binding of benzocaine because of the fast kinetics of benzocaine binding to the channels. 7,31,32 MTS-L0-BZ shifted the steady-state inactivation curve of hH1 channels from -60.2Ϯ1.7 to -71.7Ϯ2.8 mV (nϭ7; PϽ0.01), which was not reversed on washout (-75.7Ϯ3.0 mV, nϭ7; PϽ0.01) ( Figure 2B , Table 1 ). A similar shift of the steady-state inactivation curve was observed with 500 mol/L benzocaine (-60.9Ϯ1.9 mV control versus -68.8Ϯ2.7 mV benzocaine; PϽ0.01); however, this was reversible on drug washout (-63.7Ϯ2.5 mV; nϭ4) ( Figure 2B ). These results establish that the MTS-L0-BZ can stabilize the inactivated state of hH1 Na ϩ channels in a manner similar to that observed with benzocaine.
MTS-L0-BZ (500 mol/L) also produced leftward shifts of the steady-state inactivation curves in rSkM1 channels from -54.7Ϯ0.7 to -61.2Ϯ2.0 mV (nϭ6; PϽ0.05), which could be largely restored to predrug values on washout of MTS-L0-BZ (-58.4Ϯ1.0 mV) ( Figure 2B ). However, in Y401C mutant channels, the shift in the steady-state inactivation curve was irreversible on washout of MTS-L0-BZ (-55.8Ϯ1.2 mV control; -64.7Ϯ3.8 mV MTS-L0-BZ; -67.3Ϯ2.6 mV wash, nϭ6).
To further examine the effects of MTS-L0-BZ on channel inactivation, the recovery from inactivation was measured; this gives another measure of drug binding to Na ϩ channels by providing an index of the rate of exit from the inactivated state. The recovery from inactivation for hH1 channels was best fit with a biexponential function with fast ( fast ) and slow ( slow ) time constants of 13.3Ϯ0.7 and 255Ϯ70 ms (nϭ4), respectively ( Figure 2C ). Benzocaine (500 mol/L) significantly prolonged the fast (28.2Ϯ2.9 ms, nϭ4; PϽ0.01) and slow time constants (672Ϯ157 ms) without significantly (PϾ0. 4 Effects of benzocaine on hH1 and effects of MTS-L0-BZ on hH1, rSkM1, and Y401C channels. A, Whole-cell Na ϩ currents recorded from Xenopus oocytes before, during, and after washout of 500 mol/L benzocaine (far left panel) or MTS-L0-BZ. Currents were elicited by a 50-ms depolarizing step pulse to -10 mV from a holding potential of -100 mV. Currents were normalized to peak currents in the absence of drug. Only the first 15 ms are shown. Dashed lines indicate currents recorded after drug washout. B, Voltage dependence of steady-state inactivation in the presence of and after washout of benzocaine (hH1) and MTS-L0-BZ (hH1, rSkM1, and Y401C). Data were normalized and fit with a Boltzmann function as described in Materials and Methods. C, Recovery from inactivation of hH1, rSkM1, and Y401C. Recovery was assessed using a 2-pulse protocol at a holding potential of -100 mV and fit with a biexponential function as described in Materials and Methods. Data are meanϮSEM of 4 to 8 experiments.
change slow (302Ϯ43 ms [nϭ7]) after modification and washout ( Figure 2C , Table 1 ). Furthermore, MTS-L0-BZ (500 mol/L) produced a significantly greater slowing in the rate of recovery from inactivation than 500 mol/L benzocaine (PϽ0.01), potentially because of an enhanced effective concentration or slower drug dissociation as a result of anchoring the agent. These data are consistent with a stabilization of the inactivated state by anchored MTS-L0-BZ.
MTS-L0-BZ (500 mol/L) slowed the fast rate of recovery from inactivation of rSkM1 channels from 5.3Ϯ1.0 to 18.3Ϯ3.9 ms (nϭ4; PϽ0.05), which was reversible on washout of the agent (8.2Ϯ1.7 ms) ( Figure 2C ). However, in Y401C channels, MTS-L0-BZ slowed the fast recovery rate from 4.3Ϯ0.9 to 26.5Ϯ3.3 ms (nϭ4; PϽ0.01), which remained significantly prolonged (22.1Ϯ3.5 ms, PϽ0.01) after washout ( Figure 2C ). These results demonstrate that, in contrast to wild-type rSkM1 channels, treatment with MTS-L0-BZ of hH1 or Y401C mutant rSkM1 Na ϩ channels is irreversible, which suggests covalent anchoring to the pore cysteine. However, the effects of MTS-L0-BZ on steady-state inactivation and recovery from inactivation on Y401C channels were less pronounced than those observed with hH1, which supports previous studies demonstrating that the cardiac isoform is more sensitive to local anesthetic agents than are skeletal muscle Na ϩ channels. 9, 10 Effect of MTSBN and MTSHE on hH1 Na ؉ Channels
Sulfhydryl modification of hH1 Na ϩ channels with the methanethiosulfonate derivatives reduces peak current amplitude. 20, 21 However, the effects of sulfhydryl modification on inactivation properties of the channel have not previously been studied. To determine whether the effects of MTS-L0-BZ on Na ϩ channel inactivation result simply from nonspecific consequences of the pore cysteine modification, effects of MTSBN and MTSHE on hH1 channels were examined. MTSBN is similar to MTS-L0-BZ in that an aromatic group is linked to the methanethiosulfonate moiety, whereas MTSHE mimics MTS-L0-BZ without the aminobenzyl group. Modification of hH1 channels with 500 mol/L MTSBN resulted in a 62Ϯ3% (nϭ4) reduction in peak current after modification and washout of the drug ( Figure 4A , Table 1 ). This was similar to the decrease in peak current observed with MTS-L0-BZ modification (49Ϯ8%). As with MTS-L0-BZ, MTSBN caused irreversible reductions in peak current and caused similar shifts and changes in slope factors of the steady-state inactivation relationship (Table 1) . However, the degree of slowing of the fast recovery rate by MTSBN was significantly less than that with MTS-L0-BZ (PϽ0.001).
In contrast, MTSHE had no effect on any of the inactivation parameters measured and reduced peak currents to a lesser extent than either MTS-L0-BZ or MTSBN (Table 1) . Figure 3 . Reversibility of MTS-L0-BZ modification of Y401C channels. A, Whole-cell Na ϩ currents of Y401C channels expressed in Xenopus oocytes. Currents were elicited as described in Figure 2 . Channels were modified with 500 mol/L MTS-L0-BZ for at least 10 minutes, followed by drug washout. The channels were then exposed to 10 mmol/L DTT. B, Recovery from inactivation of MTS-L0-BZ-modified channels (after washout) and after DTT exposure. Data were fit to a biexponential function as described in Values for benzocaine represent measurements after a 10-minute exposure. hH1 and rat cardiac Na ϩ channels were modified with 500 mol/L for the methanethiosulfonate compound for 10 minutes followed by washout of the drug. Data are meanϮSEM. *PϽ0.01, †PϽ0.05.
These data suggest that simple sulfhydryl modification of the channel pore does not result in alterations in channel inactivation. The effects of MTS-L0-BZ are dependent on the presence of the aromatic group, given that MTSBN elicited similar effects on both steady-state inactivation and recovery from inactivation as compared with MTS-L0-BZ.
Effect of MTS-L0-BZ on Native Cardiac Na ؉ Channels
To ensure that the isoform specificity of MTS-L0-BZ was applicable to native cardiac Na ϩ channels, the effects of MTS-L0-BZ on native rat cardiac Na ϩ currents were examined. Using the whole-cell patch-clamp recordings, MTS-L0-BZ (500 mol/L) reduced peak rat cardiac Na ϩ current ( Figure 5A ) and shifted the voltage midpoint of the steadystate inactivation relationship leftward from -68.5Ϯ1.4 to -92.8Ϯ1.7 mV (nϭ6; PϽ 0.01) ( Figure 5B ; Table 1 ). As in expressed hH1 channels, this hyperpolarizing shift was maintained despite extensive washout of the drug (V 1/2 ,-90.4Ϯ5.0 mV; Figure 5B , Table 1 ), which is consistent with irreversible anchoring of MTS-L0-BZ to native cardiac Na ϩ channels. This notion is further supported by the irreversible slowing in the rate of recovery from inactivation at -120 mV ( Figure  5C ). MTS-L0-BZ prolonged the rate of recovery from 8.3Ϯ1.5 to 46.1Ϯ3.0 ms (nϭ6; PϽ0.01) after drug modification and washout. Therefore, MTS-L0-BZ elicits similar effects on both native and heterologously expressed cardiac Na ϩ channels.
Effect of MTS-L0-BZ on the LABS
A method for further establishing if anchored MTS-L0-BZ interacts with the LABS involves examining whether MTS-L0-BZ can compete with the binding of other local anesthetics. 33 Exposure of hH1 channels to lidocaine elicited 2 distinct time components for the recovery from inactivation (data not shown). The fast component (Ͻ20 ms) reflects normal gating channels, whereas the slow component (Ͼ300 ms) is indicative of lidocaine binding to the inactivated state of the channel. 7, 8 Increasing lidocaine concentrations enhances the fraction of slowly recovering channels without altering the time constant. 7, 8 Plotting the fraction of the hH1 channels recovering at the slow time constant as a function of the lidocaine concentration allows estimation of the IC 50 for lidocaine inhibition of Na ϩ current 8 ( Figure 6 ). An IC 50 of 22Ϯ3 mol/L (nϭ5) was calculated, which is very similar to those reported previously in native Na ϩ channels (9.7 mol/L) 8 and in hH1 channels expressed in Xenopus oocytes (16 mol/L) 9 or human embryonic kidney cells (21 mol/L). 10 As expected, the local anesthetic benzocaine (500 mol/L) shifted the affinity of lidocaine for the inactivated state to 123Ϯ13 mol/L (nϭ4; PϽ0.01) (Figure 6A) . Irreversible modification of hH1 channels with Figure 4 . Effect of MTSBN and MTSHE on hH1 channels. hH1 channels were modified with 500 mol/L MTSBN (left) or MTSHE (right), followed by drug washout. A, Whole-cell currents recorded as described in Figure 2 . Dashed line indicates current after drug washout. B and C, Steady-state inactivation (B) and recovery from inactivation (C) of hH1 channels in the absence, presence, and washout of MTSBN or MTSHE. Data were fit with a Boltzmann distribution (B) or a biexponential function (C) as described in Figure 2 . Values are provided in Table 1 . Data are meanϮSEM of 4 experiments.
Figure 5. Effect of MTS-L0-BZ on native rat cardiac Na
ϩ channels. A, Whole-cell currents from isolated rat ventricular myocyte recorded at Ϫ10 mV before, during, and after 500 mol/L MTS-L0-BZ exposure. Holding potential was Ϫ120 mV. B and C, Steady-state inactivation (B) and recovery from inactivation (C) of rat cardiac Na ϩ channels in the absence, presence, and washout of MTS-L0-BZ. Data were fit as described in Figure 2 , and values are given in Table 1 . Each point represents the meanϮSEM of 6 experiments.
Li et al Drug Anchoring to Cardiac Sodium Channels
MTS-L0-BZ (500 mol/L) resulted in a 1.5-fold larger reduction in lidocaine sensitivity of the channel than benzocaine (187Ϯ29 mol/L, nϭ4; PϽ0.01) ( Figure 6B ). Recent mutagenesis studies have identified critical residues that influence local anesthetic binding to the rat brain Na ϩ channel. 12, 34 These residues are located in the sixth transmembrane-spanning region of domain IV of the Na ϩ channel ␣ subunit. One residue in particular, F1764, when mutated to alanine resulted in near-complete abolition of use-dependent and voltage-dependent block by local anesthetics. 12, 34 Similarly, alanine substitution of the equivalent residue in rSkM1 (F1579A) has been shown to reduce local anesthetic sensitivity. 35 Therefore, the effects of MTS-L0-BZ on rSkM1 Na ϩ channels containing the F1579A mutation were examined, as well as the Y401C pore mutation, to allow covalent anchoring of the drug. By comparison with Y401C channels (Figure 2B ), Y401C/F1579A mutant Na ϩ channels had a rightward-shifted voltage midpoint of the steady-state inactivation relationship from -55.8Ϯ1.2 mV (nϭ5) to -44.8Ϯ0.7 mV (nϭ5) (PϽ0.01) ( Figure 7A ) and an accelerated rate of recovery from inactivation from 4.30Ϯ0.90 ms (nϭ4) to 1.00Ϯ0.04 ms (nϭ5) (PϽ0.01) ( Figure 7A ). Modification of Y401C/F1579A mutant Na ϩ channels by 500 mol/L MTS-L0-BZ had no effect on peak current amplitude (101Ϯ4%, nϭ5) (data not shown). Furthermore, there was no significant effect on the voltage dependence of steady-state inactivation ( Figure 7A ). The voltage midpoints for the steady-state inactivation relationship were -43.3Ϯ1.1 and -44.4Ϯ1.4 mV (nϭ5) during exposure and washout of MTS-L0-BZ, respectively, which were not significantly different from control values (-44.8Ϯ0.7 mV). There was also a modest but significant slowing in the fast rate of recovery from inactivation from 1.00Ϯ0.04 to 1.23Ϯ0.06 ms (nϭ5; PϽ0.05) with 500 mol/L MTS-L0-BZ present ( Figure 7B ) and 1.30Ϯ0.06 ms (PϽ0.05) after drug washout. These data further suggest that MTS-L0-BZ modifies Na ϩ channel inactivation by binding to the local anesthetic receptor after anchoring to the external pore site.
Dependence of Channel Modification on Linker Length
The results above establish that tethering benzocaine to the sulfhydryl-reactive methanethiosulfonate group via an ethyl alkyl linker allowed irreversible modification of hH1 Na ϩ channels. On the basis of the structure of the local anesthetic MTS-L0-BZ, it is conceivable that varying the linker properties could influence drug action. Indeed, we hypothesized that excessively short linker lengths may prevent or reduce the interaction of the anchored drug with the LABS, thus decreasing drug efficacy. Alternatively, very long linkers could increase diffusion times or produce steric effects that would also reduce drug efficacy. Moreover, the precise chemical properties of the linker may also have effects on drug modification and/or delivery. Therefore, altering the linker properties may affect the ability of the MTS-L0-BZ to modify Na ϩ channels. Initially, the linker length was increased with 3, 6, or 9 alkyl groups. However, increasing the alkyl linker length reduced the drug solubility and reduced the rate of anchoring to hH1 channels at low concentrations. For that reason, linkers were constructed using polyethylether units, (-OCH 2 CH 2 -) n (nϭ1, 2, or 3), which markedly enhanced their aqueous solubility in comparison with the long alkyl linker derivatives. Extending the single sulfide linker (-S-; 0.3 nm) in MTS-L0-BZ with an ethylether sulfide unit (-O-CH 2 -CH 2 )-S-increased the linker by 3 bond lengths (extended length, 0.65 nm), which is referred to as MTS-L3-BZ. Incorporation of 2 ethylether units (-O-CH 2 -CH 2 -O-CH 2 -CH 2 )-S-produced a linker 6 bond lengths longer (extended length, 1 nm), which is referred to as MTS-L6-BZ, and so forth. The application of polyethylether-based drugs (500 mol/L) with 3, 6, or 9 bond lengths did not enhance the reduction in peak hH1 Na ϩ current (Table 2) or produce a further leftward-shift steady-state inactivation curve ( Figure  8A , Table 2 ) when compared with MTS-L0-BZ ( Figure 8A ). Indeed, shifts in the steady-state inactivation curves with the extended linker compounds followed the sequence MTS-L0-BZϾMTS-L6-BZϭbenzocaineϾMTS-L3-BZϾMTS-L9-BZ ( Figure 8A , Table 2 ).
A very different rank potency emerged when the effects of MTS-L0-BZ and the various linker lengths on recovery from inactivation were examined. MTS-L6-BZ prolonged the fast rate constant of recovery from inactivation more than MTS-L0-BZ or MTS-L3-BZ ( Figure 8B , Table 2 ). Further lengthening of the linker to 9 bond lengths (extended length, 1.35 nm) did not elicit any further modification. In fact, MTS-L9-BZ was less able to slow the rate of inactivation compared with MTS-L6-BZ (32.8Ϯ3.5 versus 92.7Ϯ11.2 ms, PϽ0.05). The rank potency for slowing the rate of recovery from inactivation was MTS-L6-BZϾMTS-L0-BZϭMTS-L3-BZϾMTS-L9-BZϭbenzocaine, which suggests that a 6-atom linker is more efficacious at modifying the recovery from inactivation properties of hH1 channels.
In addition to the marked slowing in the recovery from inactivation, MTS-LX-BZ compounds also produced usedependent reductions in peak current. When hH1 channels were depolarized to -10 mV for 20 ms (holding potential, -100 mV) at a stimulation frequency of 5 Hz, there was a 9Ϯ1% reduction in peak current amplitude measured at the 30th pulse (nϭ18, Figure 8C ). Application of 500 mol/L benzocaine produced a modest increase in use dependence as compared with control (13Ϯ1%, nϭ4, PϽ 0.05) ( Figure 8C ). All MTS-LX-BZ analogues tested at 500 mol/L resulted in a significant use-dependent reduction in peak current amplitude compared with control (measured at the 30th pulse), as shown in Figure 8C , but only MTS-L0-BZ (31Ϯ5%, nϭ3) and MTS-L6-BZ (42Ϯ5%, nϭ5) resulted in a significantly greater use dependence than benzocaine (PϽ0.01). This rank potency was similar to that seen with slowing of the recovery from inactivation.
Discussion
The application of MTS-LX-BZ compounds irreversibly modified native and expressed cardiac as well as mutant Y401C rSkM1 Na ϩ channels, unless treated with the reducing agent DTT. In contrast, the drug effects on wild-type rSkM1 Na ϩ channels were reversed on washout. The effects of MTS-LX-BZ compounds were more prominent in hH1 Na ϩ channels when compared with rSkM1 or Y401C channels, which supports previous findings that the cardiac isoform is more sensitive to local anesthetics. 9, 10 These observations establish that MTS-LX-BZ agents were anchored onto the channel via an extracellular pore cysteine uniquely found in cardiac Na ϩ channels. Anchoring these compounds to the channel pore could affect Na ϩ channels in any number of ways. For example, tethering of the drug could reduce current by simply physically occluding the pore. However, the effects of anchored MTS-LX-BZ are largely indistinguishable from those observed with benzocaine alone (although see below), which suggests that interactions between the anchored drugs and LABS are also involved. This conclusion is supported by a number of experimental observations. Drug anchoring was able to reduce the potency of lidocaine binding to the channels, which is expected if the 2 drugs were competing for the same LABS, as established previously. 7, 33 Additionally, mutation of the phenylalanine residue (ie, F1579A) located in S6 of domain IV abolished the effects of anchored benzocaine. This residue has been shown to reduce both tonic and phasic block by local anesthetics in Na ϩ channels, 12, 34, 35 as expected if this residue forms an important part of the local anesthetic receptor. Finally, anchored compounds such as MTSHE (Figure 4) or MTS-LX (ie, linkers alone attached to MTS), which lack the aromatic portion of MTS-LX-BZ (data not shown), did not have the effects on Na ϩ current characteristically associated with the aromatic structures of local anesthetics. 36, 37 On the other hand, the aromatic compound MTSBN did produce local anesthetic-like modulation of channel function (Figure 4) , which suggests that the chemical interaction of the aromatic group is required for interaction with the LABS, consistent with previous studies involving benzene 36 and phenol. 37 Despite evidence for the involvement of interactions between anchored MTS-LX-BZ agents and the LABS, probably via the aromatic structure, some of the reductions in peak current (Table 1) can be attributed to the partial occlusion of the pore. Indeed, MTSHE and MTS-LX modification caused a Ϸ25% reduction in peak current but, again, without significantly affecting other channel properties. hH1 channels were modified with 500 mol/L for 10 minutes followed by washout of the drug. Data are meanϮSEM.
*PϽ0.01, †PϽ0.05.
Local anesthetics modify Na ϩ channels by dynamically binding and unbinding to their binding site in a time-and voltage-dependent manner. This behavior readily explains the leftward shifts in steady-state inactivation, use-dependent blockade, and slowed rates of recovery from inactivation. Because modification of Na ϩ channels by anchored MTS-LX-BZ closely resembles the changes by benzocaine, our results demonstrate that the interaction of the anchored drug with the LABS involves dynamic, voltage-dependent binding and unbinding, presumably of the aromatic portion of the drug. This dynamic binding of the anchored MTS-LX-BZ compounds could arise from voltage-dependent changes in the intrinsic affinity of the drug for the LABS or possibly from voltage-dependent changes in the spatial arrangement of the anchored drug to the LABS or both. In essence, the anchoring of MTS-LX-BZ agents should increase the apparent local anesthetic concentration at the extracellular face of the channel to extremely high levels. This would be expected to produce a very potent block, and indeed MTS-L0-BZ causes larger shifts in the steady-state inactivation curves than 500 mol/L benzocaine. However, the extent of channel modification by these anchored compounds also depends on energetic, steric, and entropic factors that are probably very different from unanchored local anesthetics. For example, if interactions with the LABS require protein distortion, the apparent affinity of drug binding will be reduced. Alternatively, the anchored drug might bind to other sites remote from LABS or cause local changes of the channel protein structure in the anchored region, thereby reducing the apparent binding affinity for the LABS.
Application of MTS-L0-BZ to cardiac and Y401C channels results in the tethering of benzocaine to an external pore residue via a linker with an approximate length of 0.3 nm when fully extended (ie, -S-). The extent of channel modification by anchored MTS-L0-BZ was more potent than that observed after the application of 500 mol/L free benzocaine. Although initially surprising, this result is not entirely unexpected. For example, P-loop residues involved in forming the putative selectivity filter of Na ϩ channels can influence local anesthetic access and binding of the drug with its receptor. 38, 39 In addition, as outlined above, previous studies have demonstrated that the pore-lining residues and the LABS are in close proximity within the channel pore. The fractional electrical distance (␦) of the pore-lining cardiac-specific cysteine in domain I was estimated to be 0.21 14 from the outside, whereas ␦ is estimated to be 0.7 for the local anesthetic blocking site 18 from the cytoplasmic side. Assuming that the voltage drop within the pore occurs over a span of 3 nm, these data suggest that the axial distance between the anchoring site and the LABS is Ͻ0.3 nm. However, this distance could be grossly overestimated if the Na ϩ channel structure in the P-loop region resembles that of K ϩ channels. In Shaker K ϩ channels, 80% of the voltage drop occurs between residues Y449 and T441. 40 Assuming that the recently published crystal structure of the K ϩ channel derived from Streptomyces lividans (KcsA) is representative of Shaker K ϩ channel pores, the bulk of the voltage drop occurs over a distance of only 1.2 nm. 41 In any event, our results suggest that the pore cysteine in cardiac Na ϩ channels is located a very short distance from the LABS.
The potency of the different anchored MTS-LX-BZ compounds depended on channel property studied and did not, at first glance, follow an obvious pattern with respect to linker length. Because steady-state inactivation conveys information on the properties of Na ϩ channel inactivation at equilibrium, it should give a thermodynamic measure of the energetics of binding to the channel. The degree of shift in steady-state inactivation decreased with increasing chain length, which suggests that anchored MTS-L0-BZ and MTSBN, with a linker length of only 0.6 nm (-S-CH 2 ), bind more strongly to the LABS than do the longer compounds. However, we cannot rule out the possibility that kinetic factors might also play a role, because the pulses used in these studies were limited to 50 ms to prevent slow inactivation. Alternatively, Table 2 . C, Use dependence of the MTS-LX-BZ analogues on peak hH1 currents. Currents were elicited by 20-ms depolarizing step pulses to Ϫ10 mV from a holding potential of Ϫ100 mV at a stimulation frequency of 5 Hz. Oocytes were modified with MTS-LX-BZ analogues for at least 10 minutes followed by drug washout. Benzocaine data as shown in Figure 2 are plotted for comparison. Fitted values are given in Table 2 . Data represent the meanϮSEM of 24 experiments for control and 3 to 7 experiments for benzocaine and MTS-LX-BZ compounds.
the interaction of the linker with the channel may also contribute to the differences observed between the different linker length and contribute to the energetics of drug binding. Structure-activity studies on local anesthetics have revealed that small changes in drug structure can influence both state-dependent binding and potency. 32, [42] [43] [44] In contrast to the steady-state inactivation curves, rates of recovery from inactivation and use-dependent measurements are strongly influenced by the kinetics of drug interaction. Our results show that MTS-L6-BZ slowed recovery from inactivation to a greater extent and elicited greater usedependent reductions in peak current than the other compounds tested, whereas MTS-L0-BZ had a more potent effect on these parameters than either MTS-L3-BZ or MTS-L9-BZ. Interestingly, MTSBN was less effective than the MTS-LX-BZ compounds at prolonging the recovery from inactivation. The more potent effects of MTS-L6-BZ compared with compounds with a shorter linker might simply reflect easier access of the benzocaine moiety to the LABS possibly because of reduced mechanical strain of the channel. However, this explanation would not readily explain the greater efficacy of MTS-L0-BZ compared with MTS-L3-BZ. Longer linkers, on the other hand, may result in slower diffusion times for drug interaction with the local anesthetic receptor. As already mentioned, the physiochemical properties of the linker could have a strong influence on the affinity and kinetics of binding to the LABS. One potential explanation for the pattern observed is that, as the linker length is increased, drug binding to the LABS is energetically destabilized, but the kinetics of drug binding and unbinding are slowed. The rates of recovery from inactivation and use dependence would therefore depend on a balance between changes in energetics and kinetics with length. Similar results were obtained previously using various analogues of benzocaine, establishing that the affinities and kinetics of binding to Na ϩ channels depend critically on drug structure. 32 Regardless, the pattern of channel modification with linker length demonstrates that factors other than the physical length of the linker are important determinants of anchored drug action. Further studies using linkers with different chemical structures may provide further insights into these experimental observations, and we are currently investigating these possibilities.
In summary, we created novel compounds comprised of the following 3 components: an anchoring domain (MTS), a variable-length linker, and the generic nonselective local anesthetic (benzocaine). These anchor-linker-drug compounds were found to selectively modify the cardiac Na ϩ channel homologue by anchoring the local anesthetic, benzocaine, to the unique external free sulfhydryl and subsequently dynamically binding and unbinding to the LABS. Despite their selectivity, these agents might prove to have limited therapeutic value as tissue-specific local anesthetics because of possible reactions with other free sulfhydryl groups or because covalent modification, via disulfide links, may produce long-lived complexes that may have undesirable consequences. However, selective delivery of local anesthetics to Na ϩ channels may not necessitate covalent modification of target proteins but, rather, could involve reversible binding of an "anchor" to a unique epitope, thereby effectively increasing the apparent local concentration of the nonselective drug. Indeed, we are currently designing anchor-linker-drug compounds using this approach to develop tissue-specific Na ϩ and Ca 2ϩ channel modifiers. We believe that this approach may prove to be of general utility in targeting inherently nonselective drugs to a single member of a homologous protein family via a selective anchor.
